News CMS's Medicare price negotiations start round three The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.
News Lundbeck bows out of bidding war for Avadel Lundbeck won't raise its offer to buy Avadel any further, clearing the way for the sleep disorder specialist to complete a merger with Alkermes.
News Alkermes offers more for Avadel after Lundbeck bid Alkermes has been forced to raise its offer for narcolepsy drug developer Avadel Pharma, after a rival bid from Lundbeck was deemed superior.
News Lundbeck makes bid for Avadel, trying to displace Alkermes Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its narcolepsy product.
News Lundbeck retreats from dozens of markets, slashing staff Lundbeck has announced a major change to its commercial strategy, withdrawing from 27 markets and handing day-to-day operations to partners.
News Lundbeck planning for four novel drugs in phase 3 in 2026 Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from
News Quartet of biotechs join Nasdaq after stellar IPOs Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, raising over $1.2bn.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
